Generated by AI
Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclonal antibody being studied for congenital hyperinsulinism and other forms of hypoglycemia caused by hyperinsulinism. The company’s pipeline also includes additional candidates aimed at conditions such as diabetic macular edema, reflecting a broader focus on endocrine and metabolic disorders. Rezolute Inc. works at the intersection of rare disease research and targeted drug development, with its programs designed to address serious conditions that have limited treatment options. Based in Redwood City, California, the company plays a specialized role in the biopharmaceutical market by advancing therapies for ultra-rare pediatric and metabolic diseases.
Website275 Shoreline Drive
Redwood City, CA, 94065
United States
The latest articles about RZLT.
Summary of Nov 13's posts. Generated by AI.
Summary of Oct 5's posts. Generated by AI.
Summary of Oct 5's posts. Generated by AI.
Investors talking about RZLT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.